- Home
- WHF vs VXRT Comparison
WHF vs VXRT Comparison
Compare WHF & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- VXRT
- Stock Information
- Founded
- WHF 2011
- VXRT N/A
- Country
- WHF United States
- VXRT United States
- Employees
- WHF N/A
- VXRT N/A
- Industry
- WHF Finance Companies
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WHF Finance
- VXRT Health Care
- Exchange
- WHF Nasdaq
- VXRT Nasdaq
- Market Cap
- WHF 243.6M
- VXRT 200.3M
- IPO Year
- WHF 2012
- VXRT N/A
- Fundamental
- Price
- WHF $10.49
- VXRT $0.60
- Analyst Decision
- WHF Hold
- VXRT Strong Buy
- Analyst Count
- WHF 4
- VXRT 2
- Target Price
- WHF $12.25
- VXRT $3.00
- AVG Volume (30 Days)
- WHF 88.7K
- VXRT 1.6M
- Earning Date
- WHF 11-07-2024
- VXRT 11-13-2024
- Dividend Yield
- WHF 14.67%
- VXRT N/A
- EPS Growth
- WHF N/A
- VXRT N/A
- EPS
- WHF 0.45
- VXRT N/A
- Revenue
- WHF $97,441,000.00
- VXRT $16,760,000.00
- Revenue This Year
- WHF N/A
- VXRT $67.95
- Revenue Next Year
- WHF N/A
- VXRT N/A
- P/E Ratio
- WHF $23.44
- VXRT N/A
- Revenue Growth
- WHF N/A
- VXRT 303.27
- 52 Week Low
- WHF $10.42
- VXRT $0.52
- 52 Week High
- WHF $13.44
- VXRT $1.54
- Technical
- Relative Strength Index (RSI)
- WHF 26.25
- VXRT 31.25
- Support Level
- WHF $10.49
- VXRT $0.67
- Resistance Level
- WHF $11.79
- VXRT $0.65
- Average True Range (ATR)
- WHF 0.22
- VXRT 0.05
- MACD
- WHF -0.07
- VXRT -0.01
- Stochastic Oscillator
- WHF 5.11
- VXRT 10.72
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.